Enovis Corporation

19 days ago · zacks.com

Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

19 days ago · zacks.com

Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

20 days ago · zacks.com

ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.

21 days ago · seekingalpha.com

Enovis Corporation (ENOV) M&A Call Transcript

21 days ago · marketbeat.com

Enovis NYSE: ENOV said it has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, in a move the orthopedic company said will expand its enabling-technology capabilities and accelerate its pathway into robotic surgery.

21 days ago · prnewswire.com

eCential Robotics platform to join Enovis' enabling technology portfolio. GRENOBLE, France and FRANKLIN, Tenn.

21 days ago · globenewswire.com

Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire eCential Robotics, a leading developer of enabling technologies and surgical robotics. The acquisition expands the ASTRA™ enabling technology platform with robotic automation capabilities, creating a more comprehensive ecosystem designed to improve surgical precision, streamline workflows, and enhance patient outcomes.

22 days ago · globenewswire.com

Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Fargo HealthCare conference on Tuesday, September 8, 2026 at the Encore Boston Harbor.

1 month ago · seekingalpha.com

Enovis Corporation is rated a buy, trading at a 7x EBITDA multiple versus a sector median of 14.7x, with significant upside if Arvis succeeds. Arvis, a zero-footprint, wearable augmented reality device for orthopedic surgery, targets the fast-growing ambulatory surgery center market and recently achieved full commercialization. ENOV's fundamentals are weak—slim margins, high leverage, and thin free cash flow—but these are already priced in, while Arvis's growth potential is not.

1 month ago · seekingalpha.com

Enovis is gaining share in joint reconstruction, leveraging new products and capitalizing on competitor disruptions. Q2 results beat expectations, with 4% organic revenue growth and improved margins, but guidance now anticipates a more Q4-weighted second half. ENOV is making progress on cash flow conversion and deleveraging, and should reach sub-2.0x net debt/EBITDA within three years.